Kidney drug trial for newborns halted before it began
NCT ID NCT04786574
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to see if the drug tolvaptan could help infants with a severe form of polycystic kidney disease (ARPKD) avoid needing dialysis or a kidney transplant in their first year of life. The trial was planned for babies between 28 days and 12 weeks old, but it was withdrawn before any participants were enrolled. The goal was to manage the disease and reduce the need for lifelong kidney support.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE (ARPKD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.